Autologous Matrix-induced Chondrogenesis Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2019

4.8%
CAGR (2020-2027)
230 USD Mn.
Market Size
325
Report Pages
155
Market Tables

Overview

Autologous Matrixinduced Chondrogenesis Market is expected to grow at a CAGR of 4.8% during the forecast period and market is expected to reach US$ 230 Mn. by 2027.Autologous Matrix-induced Chondrogenesis Market

To know about the Research Methodology :- Request Free Sample Report

Autologous matrix-induced chondrogenesis is a new treatment to repair articular cartilage damage. It is a just one step process that uses the microfracturing technique, which is followed by implementation of bilayer collagen I/III membrane by partially autologous fibrin glue. Rising incidence of bone and joint disorders like osteoporosis and arthritis, rising sports-related injuries, and increasing demand for minimally-invasive surgery is driving the autologous matrix-induced chondrogenesis market growth.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The scope of the report includes a detailed study of global and regional markets for Autologous Matrix-induced Chondrogenesis with the reasons given for variants in the growth of the industry in certain regions.

Rising number of joint and bone disorders like osteoporosis and arthritis globally is expected to drive the autologous matrix-induced chondrogenesis market growth throughout the forecast period. Recently, National Center for Biotechnology Information (NCBI) reported that, over XX million people are suffering from osteoporosis worldwide in every year. Similarly, increasing number of surgeries is anticipated to drive the autologous matrix-induced chondrogenesis market growth throughout the forecast period. In 2019, American Academy of Orthopaedic Surgeon (AAOS) reported that, around XX K knee replacements are performed each year in the U.S. On the other hand, ineffective structure of reimbursement and high cost of cartilage replacement are key factors hamper the growth of autologous matrix-induced chondrogenesis market. Apart from this factor, an increasing frequency of joint and bone disorders and advanced technologies available for surgeries are the crucial factors responsible for market growth.

The report on Autologous Matrix-induced Chondrogenesis market covers segments such as Material Type, Application and Region. The Material Type segment includes Hyaluronic Acid, Collagen, Polyethylene glycol (PEG), Polylactic-co-glycolic acid (PGLA), and Others. Among the Material Type, Collagen is accounted for the largest XX% market share in the Pediatric Neuroblastoma Treatment market. The Application segment is further sub-segmented into Knee Cartilage, Elbow Cartilage, and Hip Cartilage. Among the Application, Knee Cartilage is accounted for the largest XX% market share in the Pediatric Neuroblastoma Treatment market.

Based on regional segment, the Autologous Matrix-induced Chondrogenesis market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to hold leading position in the autologous matrix-induced chondrogenesis market throughout the forecast period, due to rising sports-related injuries and increasing population. For example, recently, National Safety Council (NSC) reported that, over XX K sports associated injuries were registered in the U.S. Asia Pacific is anticipated to witness noteworthy growth during forecast period, due to increasing demand for minimally-invasive surgery in the region. National Center for Biotechnology Information recently stated that, minimally-invasive surgery was carried out firstly in China and Laparoscopy surgery is one of the first types of minimally-invasive surgery. Europe, Germany, and France accounted more than 45% share of the total Europe autologous matrix-induced chondrogenesis market.

Key players operating in the Autologous Matrix-induced Chondrogenesis market are Biotissue AG, Arthro-Kinetics, JRL Orthopaedic Ltd, B Braun, Melsungen AG, Matricel GmbH, Geistlich Pharma AG, Anika Therapeutics, Inc., CartiHeal, Smith & Nephew plc, and Zimmer Biomet Holdings. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Autologous Matrix-induced Chondrogenesis market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Autologous Matrix-induced Chondrogenesis market.

Scope of the Autologous Matrix-induced Chondrogenesis Market: Inquire before buying

Autologous Matrix-induced Chondrogenesis Market, By Material Type

• Hyaluronic Acid
• Collagen
• Polyethylene glycol (PEG)
• Polylactic-co-glycolic acid (PGLA)
• Others

Autologous Matrix-induced Chondrogenesis Market, By Application

• Knee Cartilage
• Elbow Cartilage
• Hip Cartilage

Autologous Matrix-induced Chondrogenesis Market, By Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America

Key players operating in the Global Autologous Matrix-induced Chondrogenesis Market

• Biotissue AG
• Arthro-Kinetics
• JRL Orthopaedic Ltd
• B Braun
• Melsungen AG
• Matricel GmbH
• Geistlich Pharma AG
• Anika Therapeutics, Inc.
• CartiHeal
• Smith & Nephew plc.
• Zimmer Biomet Holdings

Table of Contents

Autologous Matrix-induced Chondrogenesis Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Autologous Matrix-induced Chondrogenesis Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Autologous Matrix-induced Chondrogenesis Market Analysis and Forecast 6.1. Global Autologous Matrix-induced Chondrogenesis Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Autologous Matrix-induced Chondrogenesis Market Analysis and Forecast, By Material Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Material Type 7.4. Global Autologous Matrix-induced Chondrogenesis Market Size (US$ Mn) Forecast, By Material Type 7.5. Global Autologous Matrix-induced Chondrogenesis Market Analysis, By Material Type 7.6. Global Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis, By Material Type 8. Autologous Matrix-induced Chondrogenesis Market Analysis and Forecast, By Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Application 8.4. Global Autologous Matrix-induced Chondrogenesis Market Size (US$ Mn) Forecast, By Application 8.5. Global Autologous Matrix-induced Chondrogenesis Market Analysis, By Application 8.6. Global Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis, By Application 9. Autologous Matrix-induced Chondrogenesis Market Analysis, by Region 9.1. Global Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, by Region 9.2. Global Autologous Matrix-induced Chondrogenesis Market Size (US$ Mn) Forecast, by Region 9.3. Global Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis, by Region 10. North America Autologous Matrix-induced Chondrogenesis Market Analysis 10.1. Key Findings 10.2. North America Autologous Matrix-induced Chondrogenesis Market Overview 10.3. North America Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Material Type 10.4. North America Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 10.4.1. Hyaluronic Acid 10.4.2. Collagen 10.4.3. Polyethylene glycol (PEG) 10.4.4. Polylactic-co-glycolic acid (PGLA) 10.4.5. Others 10.5. North America Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Application 10.6. North America Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 10.6.1. Knee Cartilage 10.6.2. Elbow Cartilage 10.6.3. Hip Cartilage 10.7. North America Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, by Country 10.8. North America Autologous Matrix-induced Chondrogenesis Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Autologous Matrix-induced Chondrogenesis Market Analysis, by Country 10.10. U.S. Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 10.10.1. Hyaluronic Acid 10.10.2. Collagen 10.10.3. Polyethylene glycol (PEG) 10.10.4. Polylactic-co-glycolic acid (PGLA) 10.10.5. Others 10.11. U.S. Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 10.11.1. Knee Cartilage 10.11.2. Elbow Cartilage 10.11.3. Hip Cartilage 10.12. Canada Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 10.12.1. Hyaluronic Acid 10.12.2. Collagen 10.12.3. Polyethylene glycol (PEG) 10.12.4. Polylactic-co-glycolic acid (PGLA) 10.12.5. Others 10.13. Canada Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 10.13.1. Knee Cartilage 10.13.2. Elbow Cartilage 10.13.3. Hip Cartilage 10.14. North America Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis 10.14.1. By Material Type 10.14.2. By Application 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Autologous Matrix-induced Chondrogenesis Market Analysis 11.1. Key Findings 11.2. Europe Autologous Matrix-induced Chondrogenesis Market Overview 11.3. Europe Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Material Type 11.4. Europe Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 11.4.1. Hyaluronic Acid 11.4.2. Collagen 11.4.3. Polyethylene glycol (PEG) 11.4.4. Polylactic-co-glycolic acid (PGLA) 11.4.5. Others 11.5. Europe Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Application 11.6. Europe Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 11.6.1. Knee Cartilage 11.6.2. Elbow Cartilage 11.6.3. Hip Cartilage 11.7. Europe Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, by Country 11.8. Europe Autologous Matrix-induced Chondrogenesis Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Autologous Matrix-induced Chondrogenesis Market Analysis, by Country 11.10. Germany Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 11.10.1. Hyaluronic Acid 11.10.2. Collagen 11.10.3. Polyethylene glycol (PEG) 11.10.4. Polylactic-co-glycolic acid (PGLA) 11.10.5. Others 11.11. Germany Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 11.11.1. Knee Cartilage 11.11.2. Elbow Cartilage 11.11.3. Hip Cartilage 11.12. U.K. Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 11.12.1. Hyaluronic Acid 11.12.2. Collagen 11.12.3. Polyethylene glycol (PEG) 11.12.4. Polylactic-co-glycolic acid (PGLA) 11.12.5. Others 11.13. U.K. Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 11.13.1. Knee Cartilage 11.13.2. Elbow Cartilage 11.13.3. Hip Cartilage 11.14. France Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 11.14.1. Hyaluronic Acid 11.14.2. Collagen 11.14.3. Polyethylene glycol (PEG) 11.14.4. Polylactic-co-glycolic acid (PGLA) 11.14.5. Others 11.15. France Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 11.15.1. Knee Cartilage 11.15.2. Elbow Cartilage 11.15.3. Hip Cartilage 11.16. Italy Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 11.16.1. Hyaluronic Acid 11.16.2. Collagen 11.16.3. Polyethylene glycol (PEG) 11.16.4. Polylactic-co-glycolic acid (PGLA) 11.16.5. Others 11.17. Italy Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 11.17.1. Knee Cartilage 11.17.2. Elbow Cartilage 11.17.3. Hip Cartilage 11.18. Spain Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 11.18.1. Hyaluronic Acid 11.18.2. Collagen 11.18.3. Polyethylene glycol (PEG) 11.18.4. Polylactic-co-glycolic acid (PGLA) 11.18.5. Others 11.19. Spain Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 11.19.1. Knee Cartilage 11.19.2. Elbow Cartilage 11.19.3. Hip Cartilage 11.20. Rest of Europe Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 11.20.1. Hyaluronic Acid 11.20.2. Collagen 11.20.3. Polyethylene glycol (PEG) 11.20.4. Polylactic-co-glycolic acid (PGLA) 11.20.5. Others 11.21. Rest of Europe Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 11.21.1. Knee Cartilage 11.21.2. Elbow Cartilage 11.21.3. Hip Cartilage 11.22. Europe Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis 11.22.1. By Material Type 11.22.2. By Application 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Analysis 12.1. Key Findings 12.2. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Overview 12.3. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Material Type 12.4. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 12.4.1. Hyaluronic Acid 12.4.2. Collagen 12.4.3. Polyethylene glycol (PEG) 12.4.4. Polylactic-co-glycolic acid (PGLA) 12.4.5. Others 12.5. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Application 12.6. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 12.6.1. Knee Cartilage 12.6.2. Elbow Cartilage 12.6.3. Hip Cartilage 12.7. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, by Country 12.8. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Analysis, by Country 12.10. China Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 12.10.1. Hyaluronic Acid 12.10.2. Collagen 12.10.3. Polyethylene glycol (PEG) 12.10.4. Polylactic-co-glycolic acid (PGLA) 12.10.5. Others 12.11. China Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 12.11.1. Knee Cartilage 12.11.2. Elbow Cartilage 12.11.3. Hip Cartilage 12.12. India Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 12.12.1. Hyaluronic Acid 12.12.2. Collagen 12.12.3. Polyethylene glycol (PEG) 12.12.4. Polylactic-co-glycolic acid (PGLA) 12.12.5. Others 12.13. India Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 12.13.1. Knee Cartilage 12.13.2. Elbow Cartilage 12.13.3. Hip Cartilage 12.14. Japan Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 12.14.1. Hyaluronic Acid 12.14.2. Collagen 12.14.3. Polyethylene glycol (PEG) 12.14.4. Polylactic-co-glycolic acid (PGLA) 12.14.5. Others 12.15. Japan Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 12.15.1. Knee Cartilage 12.15.2. Elbow Cartilage 12.15.3. Hip Cartilage 12.16. ASEAN Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 12.16.1. Hyaluronic Acid 12.16.2. Collagen 12.16.3. Polyethylene glycol (PEG) 12.16.4. Polylactic-co-glycolic acid (PGLA) 12.16.5. Others 12.17. ASEAN Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 12.17.1. Knee Cartilage 12.17.2. Elbow Cartilage 12.17.3. Hip Cartilage 12.18. Rest of Asia Pacific Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 12.18.1. Hyaluronic Acid 12.18.2. Collagen 12.18.3. Polyethylene glycol (PEG) 12.18.4. Polylactic-co-glycolic acid (PGLA) 12.18.5. Others 12.19. Rest of Asia Pacific Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 12.19.1. Knee Cartilage 12.19.2. Elbow Cartilage 12.19.3. Hip Cartilage 12.20. Asia Pacific Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis 12.20.1. By Material Type 12.20.2. By Application 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Overview 13.3. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Material Type 13.4. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 13.4.1. Hyaluronic Acid 13.4.2. Collagen 13.4.3. Polyethylene glycol (PEG) 13.4.4. Polylactic-co-glycolic acid (PGLA) 13.4.5. Others 13.5. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Application 13.6. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 13.6.1. Knee Cartilage 13.6.2. Elbow Cartilage 13.6.3. Hip Cartilage 13.7. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, by Country 13.8. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Analysis, by Country 13.10. GCC Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 13.10.1. Hyaluronic Acid 13.10.2. Collagen 13.10.3. Polyethylene glycol (PEG) 13.10.4. Polylactic-co-glycolic acid (PGLA) 13.10.5. Others 13.11. GCC Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 13.11.1. Knee Cartilage 13.11.2. Elbow Cartilage 13.11.3. Hip Cartilage 13.12. South Africa Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 13.12.1. Knee Cartilage 13.12.2. Elbow Cartilage 13.12.3. Hip Cartilage 13.13. Rest of Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 13.13.1. Hyaluronic Acid 13.13.2. Collagen 13.13.3. Polyethylene glycol (PEG) 13.13.4. Polylactic-co-glycolic acid (PGLA) 13.13.5. Others 13.14. Rest of Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 13.14.1. Knee Cartilage 13.14.2. Elbow Cartilage 13.14.3. Hip Cartilage 13.15. Middle East & Africa Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis 13.15.1. By Material Type 13.15.2. By Application 13.16. PEST Analysis 13.17. Key Trends 13.18. Key Developments 14. South America Autologous Matrix-induced Chondrogenesis Market Analysis 14.1. Key Findings 14.2. South America Autologous Matrix-induced Chondrogenesis Market Overview 14.3. South America Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Material Type 14.4. South America Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 14.4.1. Hyaluronic Acid 14.4.2. Collagen 14.4.3. Polyethylene glycol (PEG) 14.4.4. Polylactic-co-glycolic acid (PGLA) 14.4.5. Others 14.5. South America Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, By Application 14.6. South America Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 14.6.1. Knee Cartilage 14.6.2. Elbow Cartilage 14.6.3. Hip Cartilage 14.7. South America Autologous Matrix-induced Chondrogenesis Market Value Share Analysis, by Country 14.8. South America Autologous Matrix-induced Chondrogenesis Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Autologous Matrix-induced Chondrogenesis Market Analysis, by Country 14.10. Brazil Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 14.10.1. Hyaluronic Acid 14.10.2. Collagen 14.10.3. Polyethylene glycol (PEG) 14.10.4. Polylactic-co-glycolic acid (PGLA) 14.10.5. Others 14.11. Brazil Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 14.11.1. Knee Cartilage 14.11.2. Elbow Cartilage 14.11.3. Hip Cartilage 14.12. Mexico Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 14.12.1. Hyaluronic Acid 14.12.2. Collagen 14.12.3. Polyethylene glycol (PEG) 14.12.4. Polylactic-co-glycolic acid (PGLA) 14.12.5. Others 14.13. Mexico Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 14.13.1. Knee Cartilage 14.13.2. Elbow Cartilage 14.13.3. Hip Cartilage 14.14. Rest of South America Autologous Matrix-induced Chondrogenesis Market Forecast, By Material Type 14.14.1. Hyaluronic Acid 14.14.2. Collagen 14.14.3. Polyethylene glycol (PEG) 14.14.4. Polylactic-co-glycolic acid (PGLA) 14.14.5. Others 14.15. Rest of South America Autologous Matrix-induced Chondrogenesis Market Forecast, By Application 14.15.1. Knee Cartilage 14.15.2. Elbow Cartilage 14.15.3. Hip Cartilage 14.16. South America Autologous Matrix-induced Chondrogenesis Market Attractiveness Analysis 14.16.1. By Material Type 14.16.2. By Application 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Route of Administrations and R&D investment 15.2.2. New Treatment Center Launches and Treatment Center Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Route of Administrations 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Biotissue AG 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Treatment Center Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Arthro-Kinetics 15.3.3. JRL Orthopaedic Ltd 15.3.4. B Braun 15.3.5. Melsungen AG 15.3.6. Matricel GmbH 15.3.7. Geistlich Pharma AG 15.3.8. Anika Therapeutics, Inc. 15.3.9. CartiHeal 15.3.10. Smith & Nephew plc. 15.3.11. Zimmer Biomet Holdings 16. Primary Key Insights

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Request Customization Download Sample